Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling
The best (set of) models per patient for a priori dosage individualization can be identified using a relatively small set of TDM samples as external evaluation. Adequately performing popPK models were identified while also excluding poor-performing models. Dose recommendations resulted in more patients within the therapeutic range for both vancomycin and imatinib. Prospective validation is necessary before clinical implementation.
Authors
- Bram C. Agema (ORCID: https://orcid.org/0000-0003-1825-2911)
- Birgit C. P. Koch (ORCID: https://orcid.org/0000-0002-1202-3643)
- Nielka P. van Erp (ORCID: https://orcid.org/0000-0003-1553-178X)
- Eline L. Giraud (ORCID: https://orcid.org/0000-0003-1628-942X)
- Stijn L.W. Koolen (ORCID: https://orcid.org/0000-0002-0973-7530)
- Brenda C. M. de Winter (ORCID: https://orcid.org/0000-0002-4452-8443)
- Ron H.J. Mathijssen (ORCID: https://orcid.org/0000-0001-5667-5697)
- Sebastiaan D. T. Sassen (ORCID: https://orcid.org/0000-0002-4525-638X)
- Ayşenur B Öztürk
- Tolra Kocher
Institutions
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- Radboud University Medical Center (NL)
- Erasmus MC Cancer Institute (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1007/s40262-024-01425-9
- Citations
- 8
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 5.67